UBS picks 2 pharma stocks that are likely to give 23-26% returns

​​Ascribing sell ratings to Lupin, Dr Reddy’s Laboratories, Zydus Lifesciences and Aurobindo Pharma, the brokerage said the US generic market has been declining and the pace could worsen.

More To Explore